Ovarian Cancer Drug Shrank Tumors in Phase 2 Study
The investigational drug rinatabart sesutecan showed sustained tumor reduction in patients with platinum-resistant ovarian cancer.
Updated on Oct. 10, 2026 in Cancer
An investigational drug called rinatabart sesutecan shrank tumors in 45.9% of participants in a recent phase 2 clinical trial. This treatment showed activity in patients with platinum-resistant ovarian cancer, a condition often difficult to treat.
Why it matters
Platinum-resistant ovarian cancer presents a significant challenge in oncology, and identifying new agents that induce durable responses is critical for extending options for patients. This finding suggests a potential new path for those whose tumors have stopped responding to standard therapies.
In Part C of the phase 1/2 RAINFOL-01 trial, 45.9% of patients with platinum-resistant ovarian cancer experienced tumor shrinkage. The median duration of this response was 12.1 months, with effectiveness observed regardless of tumor target protein levels.
The players
RAINFOL-01
A clinical trial evaluating the safety and efficacy of investigational drugs for ovarian cancer.
The details
The trial evaluated rinatabart sesutecan, an investigational therapy designed to target cancer cells. Researchers studied the drug's activity in patients whose cancer had already become resistant to platinum-based chemotherapy. The study results, reported on October 9, 2026, indicate that the treatment maintained its effect for a median of over a year, regardless of the baseline level of the target protein found within the patient's tumors.
Timeline
October 9, 2026: Clinical trial results were reported.
Health Landscape
This development represents a step in the ongoing search for effective therapies in the RAINFOL-01 trial pipeline. It highlights the focus on overcoming platinum resistance, which remains a primary barrier in current ovarian cancer care.
Patients managing platinum-resistant ovarian cancer should discuss these evolving clinical trial developments with their oncologist to understand if such therapies might fit their profile. Because this research is still in the phase 2 stage, it is important to talk with your doctor about ongoing eligibility for enrollment in clinical studies.
The takeaway
The data from the RAINFOL-01 trial highlights the potential for sustained responses in patients facing platinum-resistant ovarian cancer. Patients should track new clinical trial announcements and discuss emerging options with their oncology care team to determine their relevance to individual treatment plans.
Further reading
For more information on current treatment trends, visit our Cancer section.
